Anti-MRSA quinolones for acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials. Issue 5 (4th May 2022)

• Record Type: Journal Article
• Authors: Chao, Chien-Ming; Weng, Teng-Song; Chen, Yu-Hung; Lai, Chih-Cheng; Lin, Wei-Ting
• Is Part Of: Expert review of anti-infective therapy. Volume 20:Issue 5(2022)
• Page Start: 733
• Page End: 739
• Publication Date: 2022-05-04
• Subjects: Acute bacterial skin and skin structure infection -- delafloxacin -- levonadifloxacin -- acorafloxacin -- jnj-q2 -- methicillin-resistantstaphylococcus aureus; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2022.2004119
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Objects: This study compared the clinical efficacy and safety of anti-methicillin-resistant Staphylococcus aureus (MRSA) quinolones for treating acute bacterial skin and skin structure infections (ABSSSIs). Methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for relevant articles from inception to 21 July 2021. RCTs comparing the clinical efficacy and safety of anti-MRSA quinolones with other antibiotics for treating adult patients with ABSSSIs were included. Results: Six RCTs were included. A total of 1, 264 and 1, 307 participants received the anti-MRSA quinolone-based study group and the control group. In the study group receiving anti-MRSA quinolone-based treatment, 935, 246, and 83 patients received delafloxacin, levonadifloxacin, and acorafloxacin, respectively. No significant difference was observed in the clinical cure rate at test of cure between the study and control groups (OR, 1.08; 95% CI, 0.91–1.29; I 2 = 0%). In patients with MRSA-associated ABSSSIs, the clinical cure rate (OR, 1.09; 95% CI, 0.71–1.65; I 2 = 0%) and microbiological response rate (OR, 1.24; 95% CI, 0.48–3.21; I 2 = 0%) of anti-MRSA quinolones were similar to those of other antibiotics. Conclusions: The efficacy of anti-MRSA quinolone-based treatment is comparable to that of other anti-MRSA antibiotics for treating ABSSSIs.